Literature DB >> 3080696

MPTP: a neurotoxin relevant to the pathophysiology of Parkinson's disease. The 1985 George C. Cotzias lecture.

S H Snyder, R J D'Amato.   

Abstract

MPTP (N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) elicits selective destruction of nigrostriatal dopamine neurons in humans and animals along with clinical symptoms of parkinsonism. Recent studies clarify mechanisms accounting for this neurotoxicity. MPTP binds with high affinity to monoamine oxidase, which transforms it to the pyridinium MPP+ . MPP+ is selectively concentrated by the dopamine neuronal uptake system. In nigral cells, binding by melanin of MPP+ affords a "depot" release mechanism to maintain prolonged high intracellular concentrations sufficient to destroy cells. PC-12 cells provide a model catecholamine cell culture for screening environmentally occurring substances that may be relevant in the etiology of idiopathic Parkinson's disease.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3080696     DOI： 10.1212/wnl.36.2.250

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


  31 in total

1.  Pargyline reduces/prevents neuroleptic-induced acute dystonia in monkeys.

Authors:  R Heintz; D E Casey
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

2.  Genetic susceptibility to Parkinson's disease among South and North Indians: I. Role of polymorphisms in dopamine receptor and transporter genes and association of DRD4 120-bp duplication marker.

Authors:  Ramesh C Juyal; Mitashree Das; Sohan Punia; Madhuri Behari; Geetika Nainwal; Sumit Singh; Pazhayannur V Swaminath; Shyla T Govindappa; Sachi Jayaram; Uday B Muthane; B K Thelma
Journal:  Neurogenetics       Date:  2006-07-01       Impact factor: 2.660

3.  Interactions of the neurotoxin MPTP and its demethylated derivative (PTP) with monoamine oxidase-B.

Authors:  J P Sullivan; K F Tipton
Journal:  Neurochem Res       Date:  1992-08       Impact factor: 3.996

4.  Reduced noradrenergic innervation of ventral midbrain dopaminergic cell groups and the subthalamic nucleus in MPTP-treated parkinsonian monkeys.

Authors:  Gunasingh Jeyaraj Masilamoni; Olivia Groover; Yoland Smith
Journal:  Neurobiol Dis       Date:  2016-12-30       Impact factor: 5.996

5.  Differential vulnerability of primate caudate-putamen and striosome-matrix dopamine systems to the neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

Authors:  R Moratalla; B Quinn; L E DeLanney; I Irwin; J W Langston; A M Graybiel
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-01       Impact factor: 11.205

6.  Behavioural effects of (+)-4-propyl-9-hydroxynaphthoxazine in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

Authors:  C E Clarke; S Boyce; M A Sambrook; S M Stahl; A R Crossman
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-07       Impact factor: 3.000

7.  Lewy bodies are ubiquitinated. A light and electron microscopic immunocytochemical study.

Authors:  S Kuzuhara; H Mori; N Izumiyama; M Yoshimura; Y Ihara
Journal:  Acta Neuropathol       Date:  1988       Impact factor: 17.088

8.  An in vitro model of 1-methyl-4-phenyl-pyridinium (MPP+) toxicity: incubation of rabbit caudate nucleus slices with MPP+ followed by biochemical and functional analysis.

Authors:  T J Feuerstein; L Hedler; R Jackisch; G Hertting
Journal:  Br J Pharmacol       Date:  1988-10       Impact factor: 8.739

9.  Chimeric dopamine-norepinephrine transporters delineate structural domains influencing selectivity for catecholamines and 1-methyl-4-phenylpyridinium.

Authors:  K J Buck; S G Amara
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-20       Impact factor: 11.205

10.  Regional dopamine transporter gene expression in the substantia nigra from control and Parkinson's disease brains.

Authors:  T J Counihan; J B Penney
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-08       Impact factor: 10.154
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.